Published in Cancer Weekly, June 30th, 1997
Recent findings showed positive results in Phase II trials using thalidomide in androgen-independent metastatic prostate cancer patients. The first 18 patients treated exhibited prostate-specific antigen (PSA) declines as well as disease stabilization.
These patients have been observed since the onset of trials in early 1996 at the U.S. National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.